Back to All Combinations

RAS WT + BRAF WT + Left-sided

Intermediate Prognosis
25.00% Prevalence A General
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
RAS Wild-type BRAF Wild-type Left-sided
Recommended Treatments
FOLFOX/FOLFIRI + Cetuximab
FOLFOX/FOLFIRI + Panitumumab
Treatments to Avoid

No specific contraindications noted

Key Statistics
25.00%
Prevalence in CRC
Yes
Targetable
Clinical Notes
Best candidates for anti-EGFR therapy. Left-sided tumors have superior outcomes with anti-EGFR.
Information

Category: General

Evidence Level: A

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.